Literature DB >> 2907606

Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene.

O Segatto1, C R King, J H Pierce, P P Di Fiore, S A Aaronson.   

Abstract

Compared with normal erbB-2 gp185, mutant erbB-2 proteins generated by mutations either in the transmembrane domain or by NH2-terminal deletion are able to transform NIH 3T3 cells at a 10- to 100-fold greater efficiency. Mutant proteins of both classes show increased tyrosine kinase activity, suggesting that an abnormal level of receptor-associated tyrosine kinase activity is a major determinant of erbB-2 oncogenic potential.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2907606      PMCID： PMC365664          DOI： 10.1128/mcb.8.12.5570-5574.1988

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN： 0270-7306            Impact factor:   4.272


  21 in total

1.  The neu oncogene encodes an epidermal growth factor receptor-related protein.

Authors:  C I Bargmann; M C Hung; R A Weinberg
Journal:  Nature       Date:  1986 Jan 16-22       Impact factor: 49.962

2.  Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

Authors:  C I Bargmann; M C Hung; R A Weinberg
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

3.  A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences.

Authors:  D Martin-Zanca; S H Hughes; M Barbacid
Journal:  Nature       Date:  1986 Feb 27-Mar 5       Impact factor: 49.962

4.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.

Authors:  T Yamamoto; S Ikawa; T Akiyama; K Semba; N Nomura; N Miyajima; T Saito; K Toyoshima
Journal:  Nature       Date:  1986 Jan 16-22       Impact factor: 49.962

5.  A membrane-anchored cytoplasmic domain of the human insulin receptor mediates a constitutively elevated insulin-independent uptake of 2-deoxyglucose.

Authors:  L Ellis; D O Morgan; E Clauser; R A Roth; W J Rutter
Journal:  Mol Endocrinol       Date:  1987-01

6.  Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

Authors:  C R King; M H Kraus; S A Aaronson
Journal:  Science       Date:  1985-09-06       Impact factor: 47.728

7.  A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma.

Authors:  K Semba; N Kamata; K Toyoshima; T Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

8.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.

Authors:  L Coussens; T L Yang-Feng; Y C Liao; E Chen; A Gray; J McGrath; P H Seeburg; T A Libermann; J Schlessinger; U Francke
Journal:  Science       Date:  1985-12-06       Impact factor: 47.728

9.  Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts.

Authors:  C Shih; L C Padhy; M Murray; R A Weinberg
Journal:  Nature       Date:  1981-03-19       Impact factor: 49.962

10.  The v-sis/PDGF-2 transforming gene product localizes to cell membranes but is not a secretory protein.

Authors:  K C Robbins; F Leal; J H Pierce; S A Aaronson
Journal:  EMBO J       Date:  1985-07       Impact factor: 11.598
View more
  41 in total

1.  A putative molecular-activation switch in the transmembrane domain of erbB2.

Authors:  Sarel J Fleishman; Joseph Schlessinger; Nir Ben-Tal
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-02       Impact factor: 11.205

2.  Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains.

Authors:  R Murali; P J Brennan; T Kieber-Emmons; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

3.  Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas.

Authors:  B S Chozick; D L Benzil; E G Stopa; J C Pezzullo; N W Knuckey; M H Epstein; S D Finkelstein; P W Finch
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

Review 4.  Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies.

Authors:  Edwin Li; Kalina Hristova
Journal:  Biochemistry       Date:  2006-05-23       Impact factor: 3.162

5.  The erbB-2 mitogenic signaling pathway: tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein does not correlate with erbB-2 mitogenic potency.

Authors:  F Fazioli; U H Kim; S G Rhee; C J Molloy; O Segatto; P P Di Fiore
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

Review 6.  Transmembrane helix-helix interactions involved in ErbB receptor signaling.

Authors:  Florian Cymer; Dirk Schneider
Journal:  Cell Adh Migr       Date:  2010-04-13       Impact factor: 3.405

7.  Epidermal growth factor receptor, but not c-erbB-2, activation prevents lactogenic hormone induction of the beta-casein gene in mouse mammary epithelial cells.

Authors:  N E Hynes; D Taverna; I M Harwerth; F Ciardiello; D S Salomon; T Yamamoto; B Groner
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

Review 8.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

9.  Targeting HER2 in breast cancer: overview of long-term experience.

Authors:  Evan Lantz; Ivan Cunningham; Gerald M Higa
Journal:  Int J Womens Health       Date:  2010-08-09

10.  The effect of hydrophilic substitutions and anionic lipids upon the transverse positioning of the transmembrane helix of the ErbB2 (neu) protein incorporated into model membrane vesicles.

Authors:  Khurshida Shahidullah; Shyam S Krishnakumar; Erwin London
Journal:  J Mol Biol       Date:  2009-11-18       Impact factor: 5.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.